90 related articles for article (PubMed ID: 31367251)
1. MicroRNA Biogenesis is Enhanced by Liposome-Encapsulated Pin1 Inhibitor in Hepatocellular Carcinoma.
Sun D; Tan S; Xiong Y; Pu W; Li J; Wei W; Huang C; Wei YQ; Peng Y
Theranostics; 2019; 9(16):4704-4716. PubMed ID: 31367251
[TBL] [Abstract][Full Text] [Related]
2. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.
Yang D; Luo W; Wang J; Zheng M; Liao XH; Zhang N; Lu W; Wang L; Chen AZ; Wu WG; Liu H; Wang SB; Zhou XZ; Lu KP
J Control Release; 2018 Jan; 269():405-422. PubMed ID: 29170140
[TBL] [Abstract][Full Text] [Related]
3. Understanding the role of PIN1 in hepatocellular carcinoma.
Cheng CW; Leong KW; Tse E
World J Gastroenterol; 2016 Dec; 22(45):9921-9932. PubMed ID: 28018099
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.
Liao P; Zeng SX; Zhou X; Chen T; Zhou F; Cao B; Jung JH; Del Sal G; Luo S; Lu H
Mol Cell; 2017 Dec; 68(6):1134-1146.e6. PubMed ID: 29225033
[TBL] [Abstract][Full Text] [Related]
5. Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α.
Zhao R; Cheng S; Bai X; Zhang D; Fang H; Che W; Zhang W; Zhou Y; Duan W; Liang Q; Xiao L; Nie G; Hou Y
Biotechnol J; 2024 Apr; 19(4):e2400050. PubMed ID: 38651271
[TBL] [Abstract][Full Text] [Related]
6. Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma.
Lin B; Chai S; Zhang Q; Lu Y; Hu J; Zhang J; Du YZ; Wu L
Mol Pharm; 2024 Jan; 21(1):102-112. PubMed ID: 37994899
[TBL] [Abstract][Full Text] [Related]
7. Intermittent Fasting Primes the Tumor Microenvironment and Improves Nanomedicine Delivery in Hepatocellular Carcinoma.
Becker S; Momoh J; Biancacci I; Möckel D; Wang Q; May JN; Su H; Candels LS; Berres ML; Kiessling F; Hatting M; Lammers T; Trautwein C
Small; 2023 Oct; 19(43):e2208042. PubMed ID: 37376850
[TBL] [Abstract][Full Text] [Related]
8. Rapid discovery of a novel "green" and natural GST inhibitor for sensitizing hepatocellular carcinoma to Cisplatin by visual screening strategy.
Mao L; Qin Y; Fan J; Yang W; Li B; Cao L; Yuan L; Wang M; Liu B; Wang W
J Pharm Anal; 2024 May; 14(5):100923. PubMed ID: 38799232
[TBL] [Abstract][Full Text] [Related]
9. Identification of a potent and selective covalent Pin1 inhibitor.
Pinch BJ; Doctor ZM; Nabet B; Browne CM; Seo HS; Mohardt ML; Kozono S; Lian X; Manz TD; Chun Y; Kibe S; Zaidman D; Daitchman D; Yeoh ZC; Vangos NE; Geffken EA; Tan L; Ficarro SB; London N; Marto JA; Buratowski S; Dhe-Paganon S; Zhou XZ; Lu KP; Gray NS
Nat Chem Biol; 2020 Sep; 16(9):979-987. PubMed ID: 32483379
[TBL] [Abstract][Full Text] [Related]
10. tsRBase: a comprehensive database for expression and function of tsRNAs in multiple species.
Zuo Y; Zhu L; Guo Z; Liu W; Zhang J; Zeng Z; Wu Q; Cheng J; Fu X; Jin Y; Zhao Y; Peng Y
Nucleic Acids Res; 2021 Jan; 49(D1):D1038-D1045. PubMed ID: 33068436
[TBL] [Abstract][Full Text] [Related]
11. Cysteine-113 covalency inspires the development of Pin1 inhibitor.
Pu W; Li J; Peng Y
Signal Transduct Target Ther; 2020 Oct; 5(1):225. PubMed ID: 33024085
[No Abstract] [Full Text] [Related]
12. A Quality by Design Approach in Pharmaceutical Development of Non-Viral Vectors with a Focus on miRNA.
Toma I; Porfire AS; Tefas LR; Berindan-Neagoe I; Tomuță I
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890377
[TBL] [Abstract][Full Text] [Related]
13. The regulatory role of Pin1 in neuronal death.
Wang SC; Hu XM; Xiong K
Neural Regen Res; 2023 Jan; 18(1):74-80. PubMed ID: 35799512
[TBL] [Abstract][Full Text] [Related]
14. Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.
Li Y; Zhang R; Xu Z; Wang Z
Int J Nanomedicine; 2022; 17():909-925. PubMed ID: 35250267
[TBL] [Abstract][Full Text] [Related]
15. The NRF2-dependent transcriptional axis, XRCC5/hTERT drives tumor progression and 5-Fu insensitivity in hepatocellular carcinoma.
Liu T; Long Q; Li L; Gan H; Hu X; Long H; Yang L; Pang P; Wang S; Deng W
Mol Ther Oncolytics; 2022 Mar; 24():249-261. PubMed ID: 35071747
[TBL] [Abstract][Full Text] [Related]
16. Roles of peptidyl-prolyl isomerase Pin1 in disease pathogenesis.
Li J; Mo C; Guo Y; Zhang B; Feng X; Si Q; Wu X; Zhao Z; Gong L; He D; Shao J
Theranostics; 2021; 11(7):3348-3358. PubMed ID: 33537091
[TBL] [Abstract][Full Text] [Related]
17. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of the long noncoding RNA XIST suppresses glioma progression by upregulating miR-204-5p.
Shen J; Xiong J; Shao X; Cheng H; Fang X; Sun Y; Di G; Mao J; Jiang X
J Cancer; 2020; 11(15):4550-4559. PubMed ID: 32489472
[No Abstract] [Full Text] [Related]
19. Prolyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance.
Pu W; Zheng Y; Peng Y
Front Cell Dev Biol; 2020; 8():168. PubMed ID: 32296699
[TBL] [Abstract][Full Text] [Related]
20. Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma.
Cheng CW; Tse E
Front Cell Dev Biol; 2019; 7():369. PubMed ID: 32010690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
